Global Access to Commercial CAR T Cells: A Cross-Sectional Study of Health Technology Assessment in the G20

Fewer than half of FDA-approved CAR T-cell therapy indications are reimbursed by health systems in the G20 countries, despite their strong clinical benefits. Many national health technology assessments cited high costs, limited evidence maturity, logistical challenges, and uncertainty about long-term outcomes as barriers to coverage, highlighting the need for new strategies and policy interventions to expand global patient access to CAR T therapies.